GLP-1 medication reference
The short answer
This GLP-1 medication reference gives the pharmacokinetic figures — half-life, time to peak, bioavailability — for twelve products, each traced to its FDA prescribing information with the date it was read. It publishes no titration ladders and no dosing instructions. Where a label states no value, the page says so and leaves the gap rather than filling it with an estimate.
Semaglutide
The injectable and oral products share a molecule and differ enormously in absorption. Oral semaglutide's bioavailability is roughly one percent, which is why the tablet's milligram numbers look nothing like the injection's and must never be compared directly.
Ozempic Half-Life and Pharmacokinetics, Straight From the FDA Label
What the FDA-approved Ozempic label actually states about semaglutide half-life, bioavailability and time to peak, quoted with its source. Not medical advice.
Read referencePrimary-source referenceWegovy Half-Life and Pharmacokinetics, Straight From the FDA Label
What the FDA-approved Wegovy label states about semaglutide half-life, bioavailability and time to peak, each quoted with its source. Not medical advice.
Read referencePrimary-source referenceWegovy HD (Semaglutide 7.2 mg): A Primary-Source Reference
Wegovy HD is the 7.2 mg semaglutide strength listed in the FDA label. What the label states about it, and what this page will not publish. Not medical advice.
Read referencePrimary-source referenceRybelsus Bioavailability and Pharmacokinetics, From the FDA Label
The Rybelsus label puts oral semaglutide's absolute bioavailability at roughly 0.4% to 1%. What that means, quoted with its source. Not medical advice.
Read referencePrimary-source referenceOral Wegovy (Semaglutide Tablets): Pharmacokinetics From the FDA Label
What the Wegovy label states about the oral semaglutide tablet: roughly 1% to 2% bioavailability, a one-week half-life, and 25 mg among its strengths.
Read referenceTirzepatide
Two brands, one molecule, different labeled indications — and, in the labels themselves, slightly different stated half-lives. The pages keep that difference rather than averaging it away.
Mounjaro Half-Life and Pharmacokinetics, Straight From the FDA Label
What the FDA-approved Mounjaro label states about tirzepatide half-life, 80% bioavailability and time to peak, quoted with its source. Not medical advice.
Read referencePrimary-source referenceZepbound Half-Life and Pharmacokinetics, Straight From the FDA Label
The Zepbound label states a tirzepatide half-life of about 5-6 days and 80% bioavailability. Every figure quoted with its source. Not medical advice.
Read referenceLiraglutide and dulaglutide
The older weekly and daily agonists. Their labels are the most mature in this set, and also the ones where a single tidy number most often turns out not to exist — dulaglutide's bioavailability is stated separately per dose, not once.
Victoza Half-Life and Pharmacokinetics, Straight From the FDA Label
The Victoza label states a liraglutide plasma half-life of about 13 hours and roughly 55% bioavailability. Quoted with its source. Not medical advice.
Read referencePrimary-source referenceSaxenda Half-Life and Pharmacokinetics, Straight From the FDA Label
The Saxenda label states a liraglutide half-life of 13 hours, about 55% bioavailability and peak at 11 hours. Quoted with its source. Not medical advice.
Read referencePrimary-source referenceTrulicity Half-Life and Pharmacokinetics, Straight From the FDA Label
The Trulicity label gives a dulaglutide half-life of about 5 days and two different bioavailability figures, not one. Quoted with sources. Not medical advice.
Read referenceExtended-release and newer agents
An extended-release depot whose label states neither a half-life nor a bioavailability, and the first oral small-molecule agonist, whose absorption is nothing like the peptide orals above.
Exenatide Extended-Release (Bydureon BCise): A Reference Page With Two Deliberate Gaps
The Bydureon BCise label gives no absolute bioavailability and no single half-life. What it does state, and why this page omits the rest. Not medical advice.
Read referencePrimary-source referenceOrforglipron (Foundayo) Half-Life and Pharmacokinetics, From the FDA Label
The Foundayo label states an orforglipron half-life of about 29 to 49 hours and 77% bioavailability, unlike peptide orals. Quoted with its source.
Read referenceAcross every label
Pages that read across the labels rather than one product at a time: which medications exist and where each is approved, side-effect rates by trial, warnings, interactions, the pregnancy and lactation sections, injection sites, pen hardware, a glossary and a sourced statistics page. Each figure sits beside the label or named source it came from.
Primary-source referenceGLP-1 Drug Interactions: What Section 7 of Each FDA Label Says
What Section 7 of the Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound and Saxenda labels states about oral drugs, insulin, warfarin, levothyroxine and the pill.
Read reference
Primary-source referenceGLP-1 Warnings and Precautions: What Each FDA Label Actually Lists
What the FDA labels for Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound and Saxenda list under the boxed warning and Section 5, each item quoted with its source.
Read reference
Sourced reference, as of 14 September 2026GLP-1 Statistics 2026: The Numbers, Each With Its Source
GLP-1 statistics for 2026, each with a named source and date: KFF use rates, IQVIA spending, one-year discontinuation, trial averages and label side effects.
Read reference
Primary-source referenceGLP-1 Glossary: 26 Core Terms, Defined From the FDA Label
Plain definitions of GLP-1, GIP, incretin, half-life, titration, compounded vs generic and more, each traced to an FDA label or a named source.
Read reference
Primary-source referenceThe List of GLP-1 Medications, and Where Each One Is Approved (September 2026)
Every approved GLP-1 medication as of 14 September 2026: brand, molecule, maker, route, cadence and status at seven regulators, from the FDA to COFEPRIS.
Read reference
Primary-source referenceGLP-1 Pens and Needles Compared: What Each FDA Label Says About the Device
Which GLP-1 pens include a needle, which need separate pen needles, and how long each FDA label allows out of the fridge. Quoted from Section 16 and the IFUs.
Read reference
Primary-source referenceGLP-1 Pregnancy, Breastfeeding and Fertility: What Each FDA Label Says
What Section 8 of the Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda and Victoza labels says about pregnancy, lactation, fertility and registries.
Read referencePrimary-source referenceGLP-1 Side Effects by Label Frequency: What Section 6.1 of Each FDA Label Prints
Nausea, vomiting, constipation, fatigue, hair loss and injection-site rates as printed in Section 6.1 of six FDA labels, with the trial each figure came from.
Read reference
Primary-source referenceWhere to Inject a GLP-1: Abdomen, Thigh or Arm, According to Each Label
What the FDA labels for Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza and Trulicity say about abdomen, thigh and arm sites, rotation and absorption.
Read referenceWhere these numbers come from
Every figure was read from the product's own FDA prescribing information via DailyMed or FDA accessdata, and each page names the document and the date it was accessed. Not from other blogs, not from other tracking apps, not from a summary of a summary.
That sounds like a low bar and it is not. Pharmacokinetic figures propagate across the web by copying, and a number that entered circulation wrong stays wrong for years because each new page cites the last one. The only way out is to open the label.
What is deliberately missing
No titration schedules. No milligram steps, intervals, or escalation conditions. Product strengths appear only where identifying the product requires them.
A titration ladder is the single most-searched thing in this topic and publishing one would be irresponsible: it is individualised, a prescriber sets it, and a page a reader could follow is a page some reader will follow instead of their prescription.
Also missing: values a label does not state. One product here has no labeled half-life and no labeled bioavailability, and that page ships with both gaps open and explained. An estimate presented next to sourced figures would be indistinguishable from one, which is worse than no number at all.
How to use this alongside your own records
A half-life explains why a weekly injection produces a curve rather than a spike, and why the fourth or fifth dose feels different from the first even at an unchanged dose. Time to peak explains why side effects often cluster on particular days.
That is context for what you are already noticing, and it is genuinely useful in an appointment. It is not a basis for changing anything. If a figure here seems to explain a symptom, that observation belongs in a conversation with your prescriber, not in a decision you make alone.
This reference is educational and is not written or reviewed by a licensed clinician.
Why we corrected our own app's data
Building these pages meant reading twelve labels line by line, and that turned up errors in our own medication catalogue — including one bioavailability figure off by roughly five-fold, and a time-to-peak value that appears to have been carried across from a different product sharing the same molecule.
The published figures here are the labeled ones, not the ones the app shipped with. The app is being corrected to match.
That is worth saying out loud rather than quietly fixing, for two reasons. It is the reason to trust these pages — they were checked against primary sources hard enough to find real mistakes. And it is a fair warning about every other unsourced pharmacokinetic table on the internet, including the one we were previously serving.